Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Abbott Laboratories debt to equity ratio improved from 2021 to 2022 and from 2022 to 2023. |
Debt to equity ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Abbott Laboratories debt to equity ratio (including operating lease liability) improved from 2021 to 2022 and from 2022 to 2023. |
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Abbott Laboratories debt to capital ratio improved from 2021 to 2022 and from 2022 to 2023. |
Debt to capital ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Abbott Laboratories debt to capital ratio (including operating lease liability) improved from 2021 to 2022 and from 2022 to 2023. |
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Abbott Laboratories debt to assets ratio improved from 2021 to 2022 and from 2022 to 2023. |
Debt to assets ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Abbott Laboratories debt to assets ratio (including operating lease liability) improved from 2021 to 2022 and from 2022 to 2023. |
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Abbott Laboratories financial leverage ratio decreased from 2021 to 2022 and from 2022 to 2023. |
Solvency ratio | Description | The company |
---|---|---|
Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Abbott Laboratories interest coverage ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Fixed charge coverage ratio | A solvency ratio calculated as earnings before fixed charges and tax divided by fixed charges. | Abbott Laboratories fixed charge coverage ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Debt to Equity
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | —) | —) | —) | 213) | 201) | |
Current portion of long-term debt | 1,080) | 2,251) | 754) | 7) | 1,277) | |
Long-term debt, excluding current portion | 13,599) | 14,522) | 17,296) | 18,527) | 16,661) | |
Total debt | 14,679) | 16,773) | 18,050) | 18,747) | 18,139) | |
Total Abbott shareholders’ investment | 38,603) | 36,686) | 35,802) | 32,784) | 31,088) | |
Solvency Ratio | ||||||
Debt to equity1 | 0.38 | 0.46 | 0.50 | 0.57 | 0.58 | |
Benchmarks | ||||||
Debt to Equity, Competitors2 | ||||||
Cigna Group | 0.67 | 0.69 | 0.71 | 0.65 | 0.83 | |
CVS Health Corp. | 0.81 | 0.74 | 0.75 | 0.93 | 1.07 | |
Elevance Health Inc. | 0.64 | 0.66 | 0.64 | 0.60 | 0.63 | |
Humana Inc. | 0.74 | 0.75 | 0.80 | 0.51 | 0.49 | |
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Medtronic PLC | 0.47 | 0.46 | 0.51 | 0.49 | 0.51 | |
UnitedHealth Group Inc. | 0.70 | 0.74 | 0.64 | 0.66 | 0.71 | |
Debt to Equity, Sector | ||||||
Health Care Equipment & Services | 0.62 | 0.63 | 0.63 | 0.65 | 0.72 | |
Debt to Equity, Industry | ||||||
Health Care | 0.81 | 0.72 | 0.78 | 0.90 | 0.91 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Debt to equity = Total debt ÷ Total Abbott shareholders’ investment
= 14,679 ÷ 38,603 = 0.38
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Abbott Laboratories debt to equity ratio improved from 2021 to 2022 and from 2022 to 2023. |
Debt to Equity (including Operating Lease Liability)
Abbott Laboratories, debt to equity (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | —) | —) | —) | 213) | 201) | |
Current portion of long-term debt | 1,080) | 2,251) | 754) | 7) | 1,277) | |
Long-term debt, excluding current portion | 13,599) | 14,522) | 17,296) | 18,527) | 16,661) | |
Total debt | 14,679) | 16,773) | 18,050) | 18,747) | 18,139) | |
Operating lease liability, current (included in Other accrued liabilities) | 245) | 230) | 245) | 241) | 205) | |
Operating lease liability, non-current | 949) | 943) | 956) | 902) | 755) | |
Total debt (including operating lease liability) | 15,873) | 17,946) | 19,251) | 19,890) | 19,099) | |
Total Abbott shareholders’ investment | 38,603) | 36,686) | 35,802) | 32,784) | 31,088) | |
Solvency Ratio | ||||||
Debt to equity (including operating lease liability)1 | 0.41 | 0.49 | 0.54 | 0.61 | 0.61 | |
Benchmarks | ||||||
Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||
Cigna Group | 0.68 | 0.70 | 0.73 | 0.67 | 0.84 | |
CVS Health Corp. | 1.04 | 1.00 | 1.01 | 1.23 | 1.39 | |
Elevance Health Inc. | 0.66 | 0.69 | 0.67 | 0.63 | 0.65 | |
Humana Inc. | 0.77 | 0.79 | 0.84 | 0.54 | 0.53 | |
Intuitive Surgical Inc. | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Medtronic PLC | 0.49 | 0.48 | 0.53 | 0.51 | 0.51 | |
UnitedHealth Group Inc. | 0.76 | 0.80 | 0.70 | 0.73 | 0.77 | |
Debt to Equity (including Operating Lease Liability), Sector | ||||||
Health Care Equipment & Services | 0.70 | 0.71 | 0.71 | 0.74 | 0.81 | |
Debt to Equity (including Operating Lease Liability), Industry | ||||||
Health Care | 0.86 | 0.77 | 0.84 | 0.96 | 0.97 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Total Abbott shareholders’ investment
= 15,873 ÷ 38,603 = 0.41
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Abbott Laboratories debt to equity ratio (including operating lease liability) improved from 2021 to 2022 and from 2022 to 2023. |
Debt to Capital
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | —) | —) | —) | 213) | 201) | |
Current portion of long-term debt | 1,080) | 2,251) | 754) | 7) | 1,277) | |
Long-term debt, excluding current portion | 13,599) | 14,522) | 17,296) | 18,527) | 16,661) | |
Total debt | 14,679) | 16,773) | 18,050) | 18,747) | 18,139) | |
Total Abbott shareholders’ investment | 38,603) | 36,686) | 35,802) | 32,784) | 31,088) | |
Total capital | 53,282) | 53,459) | 53,852) | 51,531) | 49,227) | |
Solvency Ratio | ||||||
Debt to capital1 | 0.28 | 0.31 | 0.34 | 0.36 | 0.37 | |
Benchmarks | ||||||
Debt to Capital, Competitors2 | ||||||
Cigna Group | 0.40 | 0.41 | 0.42 | 0.40 | 0.45 | |
CVS Health Corp. | 0.45 | 0.42 | 0.43 | 0.48 | 0.52 | |
Elevance Health Inc. | 0.39 | 0.40 | 0.39 | 0.38 | 0.39 | |
Humana Inc. | 0.42 | 0.43 | 0.44 | 0.34 | 0.33 | |
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Medtronic PLC | 0.32 | 0.31 | 0.34 | 0.33 | 0.34 | |
UnitedHealth Group Inc. | 0.41 | 0.43 | 0.39 | 0.40 | 0.41 | |
Debt to Capital, Sector | ||||||
Health Care Equipment & Services | 0.38 | 0.39 | 0.39 | 0.39 | 0.42 | |
Debt to Capital, Industry | ||||||
Health Care | 0.45 | 0.42 | 0.44 | 0.47 | 0.48 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Debt to capital = Total debt ÷ Total capital
= 14,679 ÷ 53,282 = 0.28
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Abbott Laboratories debt to capital ratio improved from 2021 to 2022 and from 2022 to 2023. |
Debt to Capital (including Operating Lease Liability)
Abbott Laboratories, debt to capital (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | —) | —) | —) | 213) | 201) | |
Current portion of long-term debt | 1,080) | 2,251) | 754) | 7) | 1,277) | |
Long-term debt, excluding current portion | 13,599) | 14,522) | 17,296) | 18,527) | 16,661) | |
Total debt | 14,679) | 16,773) | 18,050) | 18,747) | 18,139) | |
Operating lease liability, current (included in Other accrued liabilities) | 245) | 230) | 245) | 241) | 205) | |
Operating lease liability, non-current | 949) | 943) | 956) | 902) | 755) | |
Total debt (including operating lease liability) | 15,873) | 17,946) | 19,251) | 19,890) | 19,099) | |
Total Abbott shareholders’ investment | 38,603) | 36,686) | 35,802) | 32,784) | 31,088) | |
Total capital (including operating lease liability) | 54,476) | 54,632) | 55,053) | 52,674) | 50,187) | |
Solvency Ratio | ||||||
Debt to capital (including operating lease liability)1 | 0.29 | 0.33 | 0.35 | 0.38 | 0.38 | |
Benchmarks | ||||||
Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||
Cigna Group | 0.40 | 0.41 | 0.42 | 0.40 | 0.46 | |
CVS Health Corp. | 0.51 | 0.50 | 0.50 | 0.55 | 0.58 | |
Elevance Health Inc. | 0.40 | 0.41 | 0.40 | 0.39 | 0.40 | |
Humana Inc. | 0.44 | 0.44 | 0.46 | 0.35 | 0.34 | |
Intuitive Surgical Inc. | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Medtronic PLC | 0.33 | 0.32 | 0.35 | 0.34 | 0.34 | |
UnitedHealth Group Inc. | 0.43 | 0.45 | 0.41 | 0.42 | 0.44 | |
Debt to Capital (including Operating Lease Liability), Sector | ||||||
Health Care Equipment & Services | 0.41 | 0.41 | 0.41 | 0.43 | 0.45 | |
Debt to Capital (including Operating Lease Liability), Industry | ||||||
Health Care | 0.46 | 0.44 | 0.46 | 0.49 | 0.49 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= 15,873 ÷ 54,476 = 0.29
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to capital ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Abbott Laboratories debt to capital ratio (including operating lease liability) improved from 2021 to 2022 and from 2022 to 2023. |
Debt to Assets
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | —) | —) | —) | 213) | 201) | |
Current portion of long-term debt | 1,080) | 2,251) | 754) | 7) | 1,277) | |
Long-term debt, excluding current portion | 13,599) | 14,522) | 17,296) | 18,527) | 16,661) | |
Total debt | 14,679) | 16,773) | 18,050) | 18,747) | 18,139) | |
Total assets | 73,214) | 74,438) | 75,196) | 72,548) | 67,887) | |
Solvency Ratio | ||||||
Debt to assets1 | 0.20 | 0.23 | 0.24 | 0.26 | 0.27 | |
Benchmarks | ||||||
Debt to Assets, Competitors2 | ||||||
Cigna Group | 0.20 | 0.22 | 0.22 | 0.21 | 0.24 | |
CVS Health Corp. | 0.25 | 0.23 | 0.24 | 0.28 | 0.31 | |
Elevance Health Inc. | 0.23 | 0.23 | 0.24 | 0.23 | 0.26 | |
Humana Inc. | 0.26 | 0.27 | 0.29 | 0.20 | 0.20 | |
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Medtronic PLC | 0.27 | 0.27 | 0.28 | 0.27 | 0.28 | |
UnitedHealth Group Inc. | 0.23 | 0.23 | 0.22 | 0.22 | 0.23 | |
Debt to Assets, Sector | ||||||
Health Care Equipment & Services | 0.23 | 0.23 | 0.23 | 0.24 | 0.26 | |
Debt to Assets, Industry | ||||||
Health Care | 0.29 | 0.27 | 0.28 | 0.30 | 0.31 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Debt to assets = Total debt ÷ Total assets
= 14,679 ÷ 73,214 = 0.20
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Abbott Laboratories debt to assets ratio improved from 2021 to 2022 and from 2022 to 2023. |
Debt to Assets (including Operating Lease Liability)
Abbott Laboratories, debt to assets (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | —) | —) | —) | 213) | 201) | |
Current portion of long-term debt | 1,080) | 2,251) | 754) | 7) | 1,277) | |
Long-term debt, excluding current portion | 13,599) | 14,522) | 17,296) | 18,527) | 16,661) | |
Total debt | 14,679) | 16,773) | 18,050) | 18,747) | 18,139) | |
Operating lease liability, current (included in Other accrued liabilities) | 245) | 230) | 245) | 241) | 205) | |
Operating lease liability, non-current | 949) | 943) | 956) | 902) | 755) | |
Total debt (including operating lease liability) | 15,873) | 17,946) | 19,251) | 19,890) | 19,099) | |
Total assets | 73,214) | 74,438) | 75,196) | 72,548) | 67,887) | |
Solvency Ratio | ||||||
Debt to assets (including operating lease liability)1 | 0.22 | 0.24 | 0.26 | 0.27 | 0.28 | |
Benchmarks | ||||||
Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||
Cigna Group | 0.21 | 0.22 | 0.22 | 0.22 | 0.24 | |
CVS Health Corp. | 0.32 | 0.31 | 0.33 | 0.37 | 0.40 | |
Elevance Health Inc. | 0.24 | 0.24 | 0.25 | 0.24 | 0.27 | |
Humana Inc. | 0.27 | 0.28 | 0.31 | 0.21 | 0.22 | |
Intuitive Surgical Inc. | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Medtronic PLC | 0.28 | 0.27 | 0.29 | 0.28 | 0.28 | |
UnitedHealth Group Inc. | 0.25 | 0.25 | 0.24 | 0.24 | 0.26 | |
Debt to Assets (including Operating Lease Liability), Sector | ||||||
Health Care Equipment & Services | 0.26 | 0.26 | 0.27 | 0.27 | 0.29 | |
Debt to Assets (including Operating Lease Liability), Industry | ||||||
Health Care | 0.31 | 0.29 | 0.30 | 0.32 | 0.33 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= 15,873 ÷ 73,214 = 0.22
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to assets ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Abbott Laboratories debt to assets ratio (including operating lease liability) improved from 2021 to 2022 and from 2022 to 2023. |
Financial Leverage
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Total assets | 73,214) | 74,438) | 75,196) | 72,548) | 67,887) | |
Total Abbott shareholders’ investment | 38,603) | 36,686) | 35,802) | 32,784) | 31,088) | |
Solvency Ratio | ||||||
Financial leverage1 | 1.90 | 2.03 | 2.10 | 2.21 | 2.18 | |
Benchmarks | ||||||
Financial Leverage, Competitors2 | ||||||
Cigna Group | 3.30 | 3.21 | 3.29 | 3.09 | 3.44 | |
CVS Health Corp. | 3.27 | 3.21 | 3.10 | 3.32 | 3.48 | |
Elevance Health Inc. | 2.77 | 2.83 | 2.70 | 2.61 | 2.44 | |
Humana Inc. | 2.89 | 2.81 | 2.76 | 2.55 | 2.42 | |
Intuitive Surgical Inc. | 1.16 | 1.17 | 1.14 | 1.15 | 1.18 | |
Medtronic PLC | 1.77 | 1.73 | 1.81 | 1.79 | 1.79 | |
UnitedHealth Group Inc. | 3.08 | 3.16 | 2.96 | 3.01 | 3.02 | |
Financial Leverage, Sector | ||||||
Health Care Equipment & Services | 2.73 | 2.73 | 2.68 | 2.70 | 2.75 | |
Financial Leverage, Industry | ||||||
Health Care | 2.80 | 2.66 | 2.77 | 2.95 | 2.93 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Financial leverage = Total assets ÷ Total Abbott shareholders’ investment
= 73,214 ÷ 38,603 = 1.90
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Abbott Laboratories financial leverage ratio decreased from 2021 to 2022 and from 2022 to 2023. |
Interest Coverage
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings | 5,723) | 6,933) | 7,071) | 4,495) | 3,687) | |
Less: Net earnings from discontinued operations, net of taxes | —) | —) | —) | 24) | —) | |
Add: Income tax expense | 941) | 1,373) | 1,140) | 497) | 390) | |
Add: Interest expense | 637) | 558) | 533) | 546) | 670) | |
Earnings before interest and tax (EBIT) | 7,301) | 8,864) | 8,744) | 5,514) | 4,747) | |
Solvency Ratio | ||||||
Interest coverage1 | 11.46 | 15.89 | 16.41 | 10.10 | 7.09 | |
Benchmarks | ||||||
Interest Coverage, Competitors2 | ||||||
Cigna Group | 4.94 | 7.43 | 6.22 | 8.76 | 5.11 | |
CVS Health Corp. | 5.20 | 3.46 | 5.16 | 4.36 | 3.96 | |
Elevance Health Inc. | 8.49 | 10.13 | 10.93 | 8.96 | 9.02 | |
Humana Inc. | 7.73 | 9.89 | 11.49 | 17.52 | 15.34 | |
Intuitive Surgical Inc. | — | — | — | — | — | |
Medtronic PLC | 9.43 | 10.98 | 5.21 | 4.71 | 4.60 | |
UnitedHealth Group Inc. | 9.97 | 13.59 | 14.44 | 13.47 | 11.55 | |
Interest Coverage, Sector | ||||||
Health Care Equipment & Services | 8.01 | 9.34 | 9.06 | 8.21 | 6.70 | |
Interest Coverage, Industry | ||||||
Health Care | 6.75 | 12.97 | 12.85 | 7.67 | 8.84 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Interest coverage = EBIT ÷ Interest expense
= 7,301 ÷ 637 = 11.46
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Abbott Laboratories interest coverage ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Fixed Charge Coverage
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings | 5,723) | 6,933) | 7,071) | 4,495) | 3,687) | |
Less: Net earnings from discontinued operations, net of taxes | —) | —) | —) | 24) | —) | |
Add: Income tax expense | 941) | 1,373) | 1,140) | 497) | 390) | |
Add: Interest expense | 637) | 558) | 533) | 546) | 670) | |
Earnings before interest and tax (EBIT) | 7,301) | 8,864) | 8,744) | 5,514) | 4,747) | |
Add: Operating lease cost | 356) | 355) | 359) | 329) | 314) | |
Earnings before fixed charges and tax | 7,657) | 9,219) | 9,103) | 5,843) | 5,061) | |
Interest expense | 637) | 558) | 533) | 546) | 670) | |
Operating lease cost | 356) | 355) | 359) | 329) | 314) | |
Fixed charges | 993) | 913) | 892) | 875) | 984) | |
Solvency Ratio | ||||||
Fixed charge coverage1 | 7.71 | 10.10 | 10.21 | 6.68 | 5.14 | |
Benchmarks | ||||||
Fixed Charge Coverage, Competitors2 | ||||||
Cigna Group | 4.64 | 6.87 | 5.61 | 7.84 | 4.67 | |
CVS Health Corp. | 3.15 | 2.16 | 3.03 | 2.75 | 2.56 | |
Elevance Health Inc. | 7.51 | 8.82 | 8.48 | 6.10 | 7.34 | |
Humana Inc. | 6.20 | 7.10 | 8.05 | 12.02 | 9.76 | |
Intuitive Surgical Inc. | 74.09 | 63.52 | 93.66 | 58.48 | 79.65 | |
Medtronic PLC | 6.90 | 7.79 | 4.31 | 3.98 | 3.97 | |
UnitedHealth Group Inc. | 7.27 | 8.77 | 8.80 | 8.51 | 7.65 | |
Fixed Charge Coverage, Sector | ||||||
Health Care Equipment & Services | 5.69 | 6.16 | 5.95 | 5.52 | 4.75 | |
Fixed Charge Coverage, Industry | ||||||
Health Care | 5.27 | 9.19 | 9.09 | 5.67 | 6.58 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= 7,657 ÷ 993 = 7.71
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Fixed charge coverage ratio | A solvency ratio calculated as earnings before fixed charges and tax divided by fixed charges. | Abbott Laboratories fixed charge coverage ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |